Lengthy famend for its wealthy historical past, putting structure, and thriving expertise sector, Prague – and Czechia as a complete – is more and more gaining recognition for one thing else: a fast-growing life sciences ecosystem. Prague’s biotech hub at the moment has so much going for it, together with world-class scientific analysis, an increasing community of revolutionary startups and specialised biotechs, the presence of huge pharma corporations, and rising investor curiosity. Put all this collectively, and it means the Czech capital is now rising as one among Central Europe’s most promising biotech hubs.
As Petra Kinzlova, chief govt officer (CEO) of Prague.bio, instructed Labiotech: “In the present day, worldwide traders explicitly view Prague not simply as an area hub, however as the first strategic ‘entry gateway’ into the broader Central and Jap European biopharma market.”
Prague: The guts of Czechia’s life sciences scene
For its dimension, Czechia’s scientific output is spectacular, and the biotech trade sits very a lot on the middle of this. In keeping with Kinzlova, the nation possesses a extremely aggressive analysis infrastructure, top-tier science, and a extremely expert workforce that may compete instantly with established European biotech hubs.
The sector includes almost 430 entities, together with corporations and analysis establishments, which generate annual revenues of CZK 97.5 billion ($4.6 billion). The trade additionally employs 32,000 extremely certified professionals, and throughout the 2024/25 tutorial yr alone, 12,000 college students have been enrolled in biology, biochemistry, and chemistry applications, making certain a sturdy expertise pipeline for future analysis and improvement (R&D) wants.
On high of this, there may be rising traction from enterprise capital and personal fairness funds. “A transparent testomony to the ecosystem’s maturity is Prague (and Prague.bio) internet hosting this yr’s BioEquity Europe, Europe’s premier biotech funding convention, marking the primary time in its 26-year historical past that the occasion has moved east of the German border to the CEE [Central and Eastern Europe] area,” mentioned Kinzlova.
Certainly, Prague itself types the beating coronary heart of Czechia’s biotech and life sciences scene, with a lot of the nation’s scientific innovation popping out of the capital.
“It’s fascinating to see how intently the native ecosystem is tied to world scientific breakthroughs and world-class names. Prague’s analysis setting has formed and linked figures like Tomáš Cihlář, senior vp at Gilead Sciences and co-developer of the worldwide HIV drug lenacapavir, in addition to Martina Benešová Schäfer and Miloslav Polášek, who’ve each made pioneering contributions to the sphere of radiopharmaceuticals,” mentioned Kinzlova.
In the present day, there are a variety of corporations based mostly in Prague internet hosting native – in addition to world – expertise, a lot of whom select to remain within the metropolis to pursue the rising variety of alternatives arising inside the biotech trade.
An eclectic combine: Promising startups, specialised corporations, and massive pharma
One among Prague’s most distinguished corporations is SOTIO Biotech, which is the most important Czech biotech firm. It’s centered on the event of focused most cancers therapies and operates on a world scale, together with in North America.
Past this, the native ecosystem additionally options extremely promising specialised corporations equivalent to DIANA Biotechnologies, which offers PCR options for diagnostic and life science labs, Adalid Sciences, which develops next-generation lipid nanoparticles for gene supply, and SigutLabs, which offers chemical synthesis providers and makes a speciality of customized synthesis and contract analysis.
Kinzlova mentioned that almost all of those key gamers are interconnected by way of the Prague.bio community, an affiliation based in 2023 that now connects round 50 key members. “This community bridges high tutorial institutes – universities (such because the College of Chemistry and Expertise in Prague or Charles College, the oldest college north of Alps and east of Rhine, based in 14th century, and others), or the institutes of the Czech Academy of Sciences, such because the Institute of Natural Chemistry and Biochemistry (IOCB Prague, the place the well-known story of antivirotics analysis of professor Antonin Holy, that led to the worldwide success of Gilead Sciences, comes from), the Institute of Molecular Genetics, and the Institute of Biotechnology – with main industrial entities like Zentiva, BMS and specialised corporations like i&i Prague, the enterprise builder, and techtransfer firm IOCB TECH.”
Moreover, the startup setting has undergone important evolution in recent times and is now way more dynamic, providing an especially favorable quality-to-cost ratio for biotech analysis. This makes the area a extremely enticing base for younger scientists from each Czechia and elsewhere across the globe to launch their initiatives.
By way of funding, Kinzlova defined that whereas enterprise capital (VC) and personal fairness funding stay robust – amounting to roughly $140 million – there was a noticeable shift in investor habits, as they’ve change into way more selective. “The variety of funding rounds has decreased, however capital is being concentrated into fewer, extra bold initiatives with bigger ticket sizes.”
Nonetheless, she famous that one of many lingering challenges in Prague and Czechia as a complete is the spin-off price: though PhD and postdoctoral college students are the first drivers behind new startups, the general price of spin-off creation within the nation stays comparatively low in comparison with Western Europe.
In the meantime, Prague can be turning into a lovely place for large pharma. Multinational companies like Bristol Myers Squibb are actively collaborating as members of the Prague.bio affiliation. Danish large Novo Nordisk has additionally not too long ago invested greater than €320 million ($364 million) in a manufacturing facility close to Prague, the place it’ll manufacture elements for diabetes and weight problems therapies.
Kinzlova mentioned that, when it comes to scale, Czechia’s total ecosystem of 430 entities and 32,000 staff is quickly approaching the dimensions of well-established European tech areas. “For comparability, Bavaria in Germany hosts 540 biotech corporations with 57,000 staff, whereas the distinguished Medicon Valley spanning Denmark and Sweden contains over 350 corporations and employs round 44,000 individuals in its personal life sciences sector.”
Prague’s biotech hub: Sustaining progress is essential
Clearly, Prague is on an upward trajectory in the case of the enlargement of its biotech and life sciences trade. However, based on Kinzlova, whereas the potential for continued progress for Prague’s biotech hub is “large”, sustaining it requires specializing in just a few essential structural pillars.
She defined: “First, we have to systematically promote the standard of our native ecosystem overseas to extend our worldwide visibility and put Prague firmly on the worldwide map. Second, we should construct a extra strong and streamlined setting for expertise switch to bridge the hole between tutorial discoveries and the industrial market. This goes hand in hand with fostering deeper, extra sensible cooperation between analysis establishments and industrial enterprises.
“Lastly,” continued Kinzlova, “due to its financial and social affect, the state ought to deal with the biotech sector as a long-term nationwide financial precedence, creating insurance policies and frameworks that may systematically entice additional enterprise capital.”
Finally, Kinzlova believes that Prague and the Central European area have all of the stipulations to change into a significant new biotech hub on the continent. “Traditionally localized, the panorama has matured quickly, and the sector is now rising a lot quicker than conventional industries. Between 2008 and 2022, the gross worth added of the life sciences sector within the CEE area grew by 130%, successfully doubling its financial contribution and proving that it’s not an missed area.”
